These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10192714)

  • 1. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa.
    Lubbe MM; Botha PL; Chalkley LJ
    Eur J Clin Microbiol Infect Dis; 1999 Jan; 18(1):46-54. PubMed ID: 10192714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro antibiotic susceptibility and molecular analysis of anaerobic bacteria isolated in Cape Town, South Africa.
    Koch CL; Derby P; Abratt VR
    J Antimicrob Chemother; 1998 Aug; 42(2):245-8. PubMed ID: 9738844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of clinically isolated anaerobic bacteria in a University Hospital Centre Split, Croatia in 2013.
    Novak A; Rubic Z; Dogas V; Goic-Barisic I; Radic M; Tonkic M
    Anaerobe; 2015 Feb; 31():31-6. PubMed ID: 25479237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008].
    Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
    Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP; Pottumarthy S; Morris AJ
    N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT; Bryskier A
    Antimicrob Agents Chemother; 2005 Jan; 49(1):408-13. PubMed ID: 15616322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.
    Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K; Fernandez HT
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1968-71. PubMed ID: 12760876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
    Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
    J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
    Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
    Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.
    Aldridge KE
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):181-6. PubMed ID: 12458126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.
    Wexler HM; Molitoris D; Finegold SM
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2222-4. PubMed ID: 10898709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibilities of bovine summer mastitis bacteria to antimicrobial agents.
    Jousimies-Somer H; Pyörälä S; Kanervo A
    Antimicrob Agents Chemother; 1996 Jan; 40(1):157-60. PubMed ID: 8787898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
    Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
    Credito KL; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4430-4. PubMed ID: 15504874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.